Moors & Cabot’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$393K Buy
1,731
+34
+2% +$6.05K 0.02% 645
2026
Q1
$293K Buy
1,697
+12
+0.7% +$2.23K 0.01% 711
2025
Q4
$336K Hold
1,685
– – 0.01% 648
2025
Q3
$264K Hold
1,685
– – 0.01% 724
2025
Q2
$256K Sell
1,685
-126
-7% -$16.8K 0.01% 711
2025
Q1
$273K Sell
1,811
-3
-0.2% -$503 0.01% 672
2024
Q4
$335K Buy
1,814
+9
+0.5% +$1.73K 0.02% 636
2024
Q3
$356K Sell
1,805
-190
-10% -$39.5K 0.02% 608
2024
Q2
$412K Buy
1,995
+18
+0.9% +$4.08K 0.02% 534
2024
Q1
$536K Sell
1,977
-299
-13% -$71.4K 0.03% 473
2023
Q4
$538K Sell
2,276
-5
-0.2% -$983 0.03% 443
2023
Q3
$447K Sell
2,281
-74
-3% -$15.2K 0.03% 469
2023
Q2
$495K Buy
2,355
+108
+5% +$21.5K 0.03% 448
2023
Q1
$453K Buy
2,247
+18
+0.8% +$4.08K 0.03% 463
2022
Q4
$486K Buy
2,229
+90
+4% +$19.7K 0.03% 432
2022
Q3
$421K Buy
2,139
+151
+8% +$32.6K 0.03% 452
2022
Q2
$425K Buy
1,988
+100
+5% +$24.4K 0.03% 458
2022
Q1
$536K Sell
1,888
-10
-0.5% -$3.08K 0.03% 448
2021
Q4
$715K Buy
1,898
+100
+6% +$38.9K 0.04% 369
2021
Q3
$743K Buy
+1,798
New +$747K 0.05% 344

Other funds holding CRL

Moors & Cabot's CRL Position: Q2 2026 in Review

Moors & Cabot increased its Charles River Laboratories (CRL) stake by 2% in Q2 2026, buying an estimated $6.05K and bringing the position to 1,731 shares worth $393K. The position accounts for 0.02% of the portfolio, ranked #645.

Moors & Cabot first reported a position in CRL in Q3 2021 and has held it in 20 quarters since. The position peaked at $743K in Q3 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Moors & Cabot held 1,731 shares of Charles River Laboratories worth $393K as of Q2 2026.
  • Moors & Cabot bought 34 Charles River Laboratories shares in Q2 2026, an estimated $6.05K.
  • Charles River Laboratories made up 0.02% of Moors & Cabot's portfolio in Q2 2026, its #645 holding.
  • Moors & Cabot first reported a position in Charles River Laboratories in Q3 2021 and has held it in 20 quarters since.
  • Moors & Cabot's Charles River Laboratories position peaked at $743K in Q3 2021.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.